See our new privacy terms at https://privacy.abbvie/.
HArmonyCa® is a collagen stimulator powered by DART™ (Dual Action Rejuvenating Technology).1,2
Its dual action formula is designed to rejuvenate your skin: hyaluronic acid (HA) provides you with an immediate lift, while calcium hydroxyapatite (CaHA) supports your body’s own collagen production for firmer, smoother skin that keeps improving over time.2,3
Reveal a refreshed, youthful look that reflects how you feel inside4,5
HArmonyCa® is a 2-in-1 facial injectable that delivers an instant and lasting lift, with results that can be seen for up to 18 months.1,2,6
HA lifts
instantly.*,7
CaHA helps your skin build more of its own collagen for a firmer, healthier look.2,8
Long-lasting results so your skin continues to look and feel better for months after treatment.1,2,6
0%
of patients saw natural-looking improvement at 1 month, and 73% reported firmer, smoother skin that kept improving up to 1 year.2
A study reported that
0%
of patients had a natural-looking improvement at 1 month, and 76% at 1 year†,‡,2
Side effects with HArmonyCa® are mostly mild and self-limiting.†,§,¶,2,5,9
2
effects
treatment
downtime
Return to work and resume most daily activities on the same day as your treatment with HArmonyCa®. This single, simple treatment has added lidocaine for a comfortable injection experience.3,9
HArmonyCa® is part of the Allergan Aesthetics advanced range of high-quality products designed to help bring your personalized treatment plan to life and make your aesthetic aspirations a reality. AA Signature can help.
To save on Allergan Aesthetics treatments and the products you know and love.
*Results derived from an animal model study comparing fillers.7
†Results from a 1-year, prospective, open-label, post-marketing study where HArmonyCa® and HArmonyCa® Lidocaine were injected in the midface of 140 patients with moderate to severe midface volume deficit. The primary endpoint was responder status based on EI-assessed MFVDS at Month 1. Secondary endpoints included responder status based on EI-assessed and participant-assessed GAIS, change from baseline on FACE-Q Satisfaction with Cheeks questionnaire, and change from baseline on FACE-Q Satisfaction with Facial Appearance questionnaire. The mITT population was all treated participants with a non-missing baseline MFVDS score. At Month 1, the MFVDS responder status (a participant with at least a 1-grade improvement on the MFVDS based on the EI’s live assessment of midface volume deficit) was 82.8% (95% CI: 75.7%–88.5%) in the mITT population for both treatment groups combined.2
‡The EI-assessed GAIS responder rate (improved or much improved) was 98.5% (132/134) at Month 1, 98.5% (130/132) at Month 3, 94.7% (126/133) at Month 6, 87.8% (115/131) at Month 9, and 75.6% (102/135) at Month 12. The participant-assessed GAIS responder rate (improved or much improved) was 91.8% (123/134) at Month 1, 86.4% (114/132) at Month 3, 81.2% (108/133) at Month 6, 75.4% (98/130) at Month 9, and 72.6% (98/135) at Month 12.2
§Results from a retrospective, non-interventional study assessing the incidence and severity of TEAEs in adults (N=403) treated with HArmonyCa® Lidocaine at six clinics in Brazil.9
¶In a post-marketing clinical analysis of HArmonyCa® (N=162), one unrelated serious AE was reported and one AE required medical intervention due to material migration into the lips and overcorrection.5
References
1. Data on file. DART trademark. Allergan Pharmaceuticals. October 28, 2025. 2. Gritti A, et al. J Cosmet Dermatol. 2025;24(9):e70430. 3. Allergan Aesthetics. HArmonyCa® Lidocaine DFU. November 14, 2025. 4. Urdiales-Gálvez F, et al. J Cosmet Dermatol. 2023;22(8):2186–2197. 5. Allergan Aesthetics. Data on file. HArmonyCa® Lidocaine. Clinical Study Report. July 2022. REF-99624. 6. Allergan Aesthetics. Data on file. ABVRRTI82655 M21-784: Safety and Efficacy. 7. Hee C, et al. Dermatol Surg. 2015;41:S373–S381. 8. Allergan Aesthetics. Data on file. ABVRRTI81261 Comparative Analysis of Bio-Stimulatory Effects. REF-139077. 9. Braz A, et al. Plast Reconstr Surg Glob Open. 2024;12(2):e5622.
Ask about how HArmonyCa® can help you achieve your aesthetic goals.
